cytochrome P450 family 4 subfamily A member 43, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4A43P profile across patient tissues and cancer cell-line models. CYP4A43P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CYP4A43P is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, CYP4A43P RNA expression shows 7,481 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, LUSC, and LUAD as cancer lineages where CYP4A43P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4A43P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4A43P survival associations across molecular data types. CYP4A43P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4A43P RNA expression–survival associations across cancer types. High CYP4A43P expression shows unfavorable associations in SKCM, STAD, LUSC, LIHC, KIRC and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CYP4A43P RNA expression.
This table summarizes CYP4A43P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4A43P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4A43P shows lower tumor expression in LUSC. The LUSC box plot shows higher CYP4A43P RNA expression in normal versus tumor tissue (log2 FC = −0.095, t-test p = .016).
This table shows molecular features associated with CYP4A43P in patient tissues and cancer cell lines. In patient samples, CYP4A43P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
